ACR-368 for high-grade endometrial cancer after prior treatments
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies ACR-368 for people with high-grade endometrial cancer that has spread or grown despite at least one prior treatment. It may help by testing whether this drug can better control the cancer after other therapies have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign written consent and agree to trial procedures.
- Your cancer diagnosis must be confirmed on tissue (biopsy/surgery) as high-grade endometrial cancer.
- Your cancer must have spread and gotten worse after at least one prior treatment regimen.
- You must have at least one measurable tumor spot on a recent scan (done within 28 days of starting treatment).
- You must have had prior platinum chemotherapy and prior anti–PD-(L)1 immunotherapy, and not too many treatment lines (no more than 3 lines for some groups, no more than 2 lines for others).
- You may need extra tumor tissue: either a new biopsy (for some study groups) or stored/archive tumor samples (for others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial is testing an experimental drug called ACR-2316 for people with certain advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug can shrink tumors or slow their growth.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy (carboplatin/paclitaxel), followed by more immunotherapy, with or without an additional targeted drug (apatinib), for advanced or recurrent endometrial cancer. It aims to see if adding the targeted drug improves outcomes.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Hear when a new Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.